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using routine prophylactic schedules for FMD 
Nick Lyons 







Vaccine effectiveness: % reduction in incidence among 
vaccinated individuals attributable to vaccination, 
measured under field conditions 
 
Reasons for poor FMD vaccine performance in the field: 
1. Poor potency 
2. Lack of vaccine match 
3. Break in the cold chain 
4. Sub-optimal coverage 
5. Interference by maternally derived antibody (MDA) 
6. Incorrect schedule 
 







Kenya, Nakuru County 
Dairy Herd: ≈350 mainly Jersey 
Last known outbreaks: March 2004 (SAT2), 
 December 2010 (NVR) 
FMD Vaccination 
Vaccinates animals every 4 months with a locally 
available quadrivalent (A, O, SAT1, SAT2) vaccine 
Only vaccinates animals over 6 months old 
Aqueous-adjuvanted, Non-NSP purified vaccine. 












Serotype O  
October-December 2013 
Last dose 3 months before 
Probable source:  Farm workers 







“Incidence risk” versus “Number of lifetime doses” 
 







“Incidence risk” versus “Number of lifetime doses” 
 









“Incidence risk” versus “Number of lifetime doses” 
 
Farm A - Vaccine 
Maternal antibody? 
Incidence plateau… 
Declining incidence implies 







40% incidence in multiply vaccinated  clearly reveals a 
problem…. 
• Potency?  
• Match? 
• Cold chain? 
 
Suboptimal schedules as well? 
 
 
Can have multiple reasons for poor VE! 
 







Kenya, Nakuru County 
Dairy Herd: ≈650 mainly Holstein-Friesian 
 
 




Vaccinates animals every 4-6 months with a locally available 
quadrivalent (A, O, SAT1, SAT2) vaccine 
Vaccinates all animals irrespective of age 
 
 







SAT2   
August – September 2012 
Last vaccination 3 months before 
Probable source: Farm workers 







“Incidence risk” versus “Number of lifetime doses” 







“Incidence risk” versus “Number of lifetime doses” 
Farm B - Vaccine 








“Incidence risk” versus “Number of lifetime doses” 
Farm B - Vaccine 
Incidence plateau among 
older animals… 








Possible reasons for incidence pattern on Farm B 
Low incidence in youngstock – poorer reporting? 
less severe disease?, less transmission/exposure? 
(like Netherlands, 2001?) 
Vaccine match? (SAT2 VP1 sequence 13% difference 
to that reported by Sangula et al, 2010) 
Vaccine potency? 
 SAT2 – known to be less stable antigen requires 









Iran, Shahriar County, Tehran Province 
Dairy herd: 3,500 cattle, Holstein-Friesian 
 
Last known outbreak 4 years previously (Not Asia-1) 
 
FMD Vaccination 
Every four months with trivalent (Asia-1 Shamir, O, A). 
Calves >2 months old get two doses one month apart 
as a primary course. 
High potency, NSP purified vaccine. 









Last dose 11 weeks before 
Probable source: Local semi- nomadic sheep/goat herds 
 







“Incidence risk” versus “Number of lifetime doses” 
 













“Incidence risk” versus “Number of lifetime doses” 
 















“Incidence risk” versus “Number of lifetime doses” 
 

















• Does appear to be evidence of some cumulative 
protection with number of doses (Farms A and C) 
• Cannot rule out other age related effects (although 
not due to exposure in these outbreaks) 
• Age distribution in the herd affects coverage! 
Vaccine protection and coverage 








Field-based vaccine performance assessments provide 
additional information on the effectiveness of a 
control policy 
Conventional laboratory-based evaluations should be 
performed alongside field evaluations 
Standardised protocols for monitoring vaccine 
performance and investigating apparent low 
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